Current concept of low-grade serous ovarian carcinoma

被引：1

作者：

Nakayama, Kentaro ^{[1
,4
]}

Razia, Sultana ^{[2
]}

Ishibashi, Tomoka ^{[1
]}

Kyo, Satoru ^{[3
]}

机构：

[1] Nagoya City Univ East Med Ctr, Dept Obstet & Gynecol, Nagoya, Japan

[2] Shimane Univ, Sch Med, Dept Legal Med, Izumo, Japan

[3] Shimane Univ, Sch Med, Dept Obstet & Gynecol, Izumo, Japan

[4] Nagoya City Univ East Med Ctr, Dept Obstet & Gynecol, 1 Chome 2-23 Wakamizu,Chikusa Ku, Nagoya, Aichi 4648547, Japan

来源：

TRANSLATIONAL CANCER RESEARCH | 2024年 / 13卷 / 01期

关键词：

Genetic alterations; low-grade serous ovarian carcinoma (LGSOC); MAPK pathway; molecular targeted therapy; overall survival (OS); MEK INHIBITOR; COMBINATION;

D O I：

10.21037/tcr-23-1161

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：6 / 10

页数：5

共 24 条

[1] EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer [J].

Arend, Rebecca C. ;

Davis, Allison M. ;

Chimiczewski, Przemyslaw ;

O'Malley, David M. ;

Provencher, Diane ;

Vergote, Ignace ;

Ghamande, Sharad ;

Birrer, Michael J. .

GYNECOLOGIC ONCOLOGY, 2020, 156 (02) :301-307

[2] Molecular features as promising biomarkers in ovarian cancer [J].

Buklaho, Patrycja Aleksandra ;

Kisluk, Joanna ;

Wasilewska, Natalia ;

Niklinski, Jacek .

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 32 (09) :1029-1040

[3] Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study [J].

Farley, John ;

Brady, William E. ;

Vathipadiekal, Vinod ;

Lankes, Heather A. ;

Coleman, Robert ;

Morgan, Mark A. ;

Mannel, Robert ;

Yamada, S. Diane ;

Mutch, David ;

Rodgers, William H. ;

Birrer, Michael ;

Gershenson, David M. .

LANCET ONCOLOGY, 2013, 14 (02) :134-140

[4] NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition [J].

Fernandez, Marta Llaurado ;

Hijmans, E. Marielle ;

Gennissen, Annemiek M. C. ;

Wong, Nelson K. Y. ;

Li, Shang ;

Wisman, G. Bea A. ;

Hamilton, Aleksandra ;

Hoenisch, Joshua ;

Dawson, Amy ;

Lee, Cheng -Han ;

Bittner, Madison ;

Kim, Hannah ;

DiMattia, Gabriel E. ;

Lok, Christianne A. R. ;

Lieftink, Cor ;

Beijersbergen, Roderick L. ;

de Jong, Steven ;

Carey, Mark S. ;

Bernards, Rene ;

Berns, Katrien .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (12) :1862-1874

[5] The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes [J].

Gershenson, David M. ;

Sun, Charlotte C. ;

Westin, Shannon N. ;

Eyada, Mostafa ;

Cobb, Lauren P. ;

Nathan, Lisa C. ;

Sood, Anil K. ;

Malpica, Anais ;

Hillman, Robert T. ;

Wong, Kwong K. .

GYNECOLOGIC ONCOLOGY, 2022, 165 (03) :560-567

[6] Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial [J].

Gershenson, David M. ;

Miller, Austin ;

Brady, William E. ;

Paul, James ;

Carty, Karen ;

Rodgers, William ;

Millan, David ;

Coleman, Robert L. ;

Moore, Kathleen N. ;

Banerjee, Susana ;

Connolly, Kate ;

Secord, Angeles Alvarez ;

O'Malley, David M. ;

Dorigo, Oliver ;

Gaillard, Stephanie ;

Gabra, Hani ;

Slomovitz, Brian ;

Hanjani, Parviz ;

Farley, John ;

Churchman, Michael ;

Ewing, Ailith ;

Hollis, Robert L. ;

Herrington, C. Simon ;

Huang, Helen Q. ;

Wenzel, Lari ;

Gourley, Charlie .

LANCET, 2022, 399 (10324) :541-553

[7] Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum [J].

Gershenson, David M. ;

Sun, Charlotte C. ;

Wong, Kwong-Kwok .

BRITISH JOURNAL OF CANCER, 2015, 113 (09) :1254-1258

[8] Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum [J].

Gershenson, David M. ;

Sun, Charlotte C. ;

Iyer, Revathy B. ;

Malpica, Anais L. ;

Kavanagh, John J. ;

Bodurka, Diane C. ;

Schmeler, Kathleen ;

Deavers, Michael .

GYNECOLOGIC ONCOLOGY, 2012, 125 (03) :661-666

[9] Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant [J].

Gershenson, David M. ;

Sun, Charlotte C. ;

Bodurka, Diane ;

Coleman, Robert L. ;

Lu, Karen H. ;

Sood, Anil K. ;

Deavers, Michael ;

Malpica, Anais L. ;

Kavanagh, John J. .

GYNECOLOGIC ONCOLOGY, 2009, 114 (01) :48-52

[10] Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer [J].

Grisham, Rachel N. ;

Sylvester, Brooke E. ;

Won, Helen ;

McDermott, Gregory ;

DeLair, Deborah ;

Ramirez, Ricardo ;

Yao, Zhan ;

Shen, Ronglai ;

Dao, Fanny ;

Bogomolniy, Faina ;

Makker, Vicky ;

Sala, Evis ;

Soumerai, Tara E. ;

Hyman, David M. ;

Socci, Nicholas D. ;

Viale, Agnes ;

Gershenson, David M. ;

Farley, John ;

Levine, Douglas A. ;

Rosen, Neal ;

Berger, Michael F. ;

Spriggs, David R. ;

Aghajanian, Carol A. ;

Solit, David B. ;

Iyer, Gopa .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4099-+

← 1 2 3 →